{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:14:49Z","timestamp":1770819289781,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00120-025-02750-y","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:10:15Z","timestamp":1766506215000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arzneimittelinteraktionen in der Uroonkologie","Drug interactions in uro-oncology"],"prefix":"10.1007","volume":"65","author":[{"given":"Elli","family":"Husso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella Maria","family":"Zraik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"9","key":"2750_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.annonc.2022.05.010","volume":"33","author":"Bessede","year":"2022","unstructured":"Bessede et\u00a0al (2022) Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 33(9):909\u2013915","journal-title":"Ann Oncol"},{"issue":"2","key":"2750_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1023\/A:1015570104121","volume":"24","author":"HJ Beijer","year":"2002","unstructured":"Beijer\u00a0HJ, de Blaey\u00a0CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a\u00a0meta-analysis of observational studies. Pharm World Sci 24(2):46\u201354","journal-title":"Pharm World Sci"},{"key":"2750_CR3","unstructured":"https:\/\/www.fachinfo.de. Zugegriffen: 26. Okt. 2025"},{"key":"2750_CR4","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/preventable-adverse-drug-reactions-focus-drug-interactions. Zugegriffen: 24. Aug. 2025"},{"key":"2750_CR5","unstructured":"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry. Zugegriffen: 9. Sept. 2025"},{"key":"2750_CR6","doi-asserted-by":"crossref","unstructured":"Gandhi TK et\u00a0al (2003) Adverse Drug events in ambulatory care. N\u00a0Engl J Med: 1556\u20131564","DOI":"10.1056\/NEJMsa020703"},{"key":"2750_CR7","unstructured":"https:\/\/kinderformularium.de\/wechselwirkungen_Pgp. Zugegriffen: 31. Aug. 2025"},{"key":"2750_CR8","unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de. Zugegriffen: 26. Okt. 2025"},{"key":"2750_CR9","unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/supportive-therapie. Zugegriffen: 26. Okt. 2025"},{"key":"2750_CR10","first-page":"736","volume":"63","author":"M Metze","year":"2022","unstructured":"Metze\u00a0M et\u00a0al (2022) Gerinnungsdiagnostik im klinischen Alltag \u2013 Teil\u00a02. Inn Med 63:736\u2013750","journal-title":"Inn Med"},{"key":"2750_CR11","unstructured":"https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/arzneimittelinteraktionen. Zugegriffen: 18. Aug. 2025"},{"issue":"1","key":"2750_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12877-024-05135-6","volume":"24","author":"RF Oliveira","year":"2024","unstructured":"Oliveira\u00a0RF et\u00a0al (2024) Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors. BMC Geriatr 24(1):557","journal-title":"BMC Geriatr"},{"issue":"1","key":"2750_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1186\/s12885-024-12947-7","volume":"24","author":"X Ren","year":"2024","unstructured":"Ren\u00a0X et\u00a0al (2024) Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a\u00a0pharmacovigilance analysis of drug-drug interactions. BMC Cancer 24(1):1193","journal-title":"BMC Cancer"},{"key":"2750_CR14","unstructured":"https:\/\/register.awmf.org\/de\/leitlinien\/detail\/nvl-005. Zugegriffen: 26. Okt. 2025"},{"issue":"15","key":"2750_CR15","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.3390\/jcm11154558","volume":"11","author":"K Schlichtig","year":"2022","unstructured":"Schlichtig\u00a0K et\u00a0al (2022) New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a\u00a0Subgroup Analysis of the AMBORA Trial. JCM 11(15):4558","journal-title":"JCM"},{"key":"2750_CR16","unstructured":"https:\/\/www.uptodate.com. Zugegriffen: 26. Okt. 2025"},{"key":"2750_CR17","unstructured":"https:\/\/www.uptodate.com\/contents\/statins-actions-side-effects-and-administration. Zugegriffen: 26. Okt. 2025"},{"key":"2750_CR18","unstructured":"https:\/\/uroweb.org\/guidelines\/prostate-cancer. Zugegriffen: 26. Okt. 2025"},{"issue":"2","key":"2750_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael\u00a0E et\u00a0al (2017) Development of a\u00a0risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39(2):424\u2013432","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2750_CR20","doi-asserted-by":"publisher","first-page":"010","DOI":"10.1093\/oncolo\/oyaf010","volume":"30","author":"LW Wu","year":"2025","unstructured":"Wu\u00a0LW, Moy\u00a0RH (2025) The complex interplay of antibiotic use and immune checkpoint inhibition. Oncologist 30(2):10","journal-title":"Oncologist"},{"key":"2750_CR21","unstructured":"https:\/\/www.who.int\/docs\/default-source\/patient-safety\/who-uhc-sds-2019-11-eng.pdf. Zugegriffen: 26. Okt. 2025"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02750-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:29:02Z","timestamp":1770816542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02750-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02750-y","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Husso erh\u00e4lt Reisekosten & Referentenhonorare von Biocon, DGOP, IUTA. M.\u00a0Wittmann und I.M.\u00a0Zraik geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}